Massive, cheap computer power – often combined with AI – has facilitated much of the recent progress in understanding and working against cancer. Accordingly, it’s good to see that research against cancer will be one of the uses for the world’s most powerful supercomputer, which is headed for  the federal government’s Argonne Labs in

After various delays, the new, more detailed ICD-10 coding takes effect in October. The ICD-10 coding is more detailed than is current coding in terms of identifying cancers by type, subtype and location. New knowledge inevitably will follow from better data. This page provides examples of the new oncology coding in general.

Here are examples

“Patent think” continues to retrench and retrace after SCOTUS’ series of unanimous rulings that ended patents for discovery of laws of nature, and for most applications of math. A cogent summary of the rulings is provided in a July 21, 2015 blog post by John Conley at the Genomics Law Report.  Unlike some never

The ongoing annual AACR meeting this week included some sort of encouraging (but far from final) news on using immunotherapy to counter mesothelioma and other awful tumors (pancreatic and ovarian tumors). The news is from an abstract for a paper focused on a research project using immunotherapy to treat tumors that express a protein known

Changes in the world of science mean that tort lawyers of today and tomorrow soon will see and learn far more about genomic mutations in tumors. Why? Because genomic analysis of tumors is becoming even more common place, and concrete steps are underway to increase the amount of and efficacy of genomic testing of tumors.

A June 13, 2014  paper by Dr. Joseph Testa and colleagues expands the ongoing investigation into the relationships among mesothelioma, asbestos fibers, pleural and peritoneal exposures, and the BAP1 mutation (both germline and somatic mutations are under investigation). The research involves creation of a line of “knockout” mice with the BAP1 mutation, and then monitoring